Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target Lowered to $6.00 at Leerink Partners

Recursion Pharmaceuticals (NASDAQ:RXRX) had its target price cut by Leerink Partners from $7.00 to $6.00 in a research report report published on Friday morning,Benzinga reports. They currently have a market perform rating on the stock.

RXRX has been the topic of several other reports. Cowen reaffirmed a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday. KeyCorp reduced their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $8.25.

Recursion Pharmaceuticals Price Performance

Shares of RXRX stock opened at $7.51 on Friday. The stock has a market cap of $2.93 billion, a price-to-earnings ratio of -4.91 and a beta of 0.86. The business’s fifty day moving average is $7.72 and its 200 day moving average is $7.08. Recursion Pharmaceuticals has a twelve month low of $5.60 and a twelve month high of $14.12. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The firm had revenue of $4.60 million during the quarter, compared to analysts’ expectations of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals’s revenue for the quarter was down 57.8% on a year-over-year basis. During the same period in the previous year, the company earned ($0.42) earnings per share. Research analysts expect that Recursion Pharmaceuticals will post -1.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. grew its stake in shares of Recursion Pharmaceuticals by 17.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company’s stock worth $12,789,000 after acquiring an additional 288,926 shares during the last quarter. Accel Wealth Management bought a new position in shares of Recursion Pharmaceuticals during the fourth quarter valued at $310,000. FMR LLC lifted its holdings in shares of Recursion Pharmaceuticals by 2.1% during the third quarter. FMR LLC now owns 8,363,530 shares of the company’s stock valued at $55,116,000 after purchasing an additional 170,810 shares in the last quarter. Avanza Fonder AB bought a new position in shares of Recursion Pharmaceuticals during the fourth quarter valued at $580,000. Finally, State Street Corp lifted its holdings in shares of Recursion Pharmaceuticals by 47.1% during the third quarter. State Street Corp now owns 12,870,272 shares of the company’s stock valued at $84,815,000 after purchasing an additional 4,120,685 shares in the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.